Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston
8
×
boston blog main
boston top stories
national blog main
san diego blog main
8
×
life sciences
clinical trials
fda
national top stories
new york blog main
san diego top stories
san francisco blog main
medical devices
indiana blog main
raleigh-durham blog main
seattle blog main
startups
boston university
boulder/denver blog main
deals
detroit blog main
drug delivery
drugs
dyne therapeutics
investing
myotonic dystrophy type 1
new york top stories
rare disease drugs
san francisco top stories
software
texas blog main
vc
venture capital
wisconsin blog main
38 studios
accelerator
aidan petrie
akcea therapeutics
alnylam pharmaceuticals
What
device
ipo
startup
ago
biotechs
boston
company
developing
drug
dyne
genetic
ipos
life
medical
medicines
million
muscle
patients
rare
science
therapeutics
time
acquire
adding
alnylam
approve
atrial
awaits
beta
better
biological
bionics
blood
boston’s
brings
business
capital
censinet
chose
city
Language
unset
Current search:
boston
×
biotech
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion